Business
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
Full year product revenue of $22.2 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada continue to progress Regulatory review ongoing
About this update from Amylyx Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nFull year product revenue of $22.2 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada continue to progress\n\n\nRegulatory review ongoing in the EU\n\n\nKaren Firestone, CEO and co-founder of Aureus Asset Management and prior fund manager at Fidelity Investments, appointed to the Company's Board of Directors\n\n\nManagement to host conference call and webcast today at 4:30 p.m. Eastern Time\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAmylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2022. The Company also announced the appointment of Karen Firestone, Chairman, CEO, and co-founder of Aureus Asset Management and prior fund manager at Fidelity Investments, to the Company’s Board of Directors, effective March 16.\n\n“2022 was an exceptionally exciting year for Amylyx, culminating with the approval of RELYVRIO in the U.S. following the approval with conditions for ALBRIOZA in Canada, marking an important step toward delivering much-needed advancements in treatment options to the ALS community,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “Our commercial launch is off to a strong start, and we are encouraged by the engagement we have seen from physicians, people living with ALS, and payors. While we are thrilled with this progress, we are also cognizant that much work remains to meet our goal of quick and efficient access for every eligible person living with ALS. With that in mind, we continue to engage with the European Medicines Agency as it reviews our Marketing Authorisation Application for AMX0035, and we remain focused on our efforts to engage stakeholders throughout the ALS community as we work to drive the broadest coverage possible for this important new therapeutic option.”\n\nCohen and Klee continued, “We are also delighted to welcome Karen Firestone from Aureus Asset Management to our Board, and we look forward to her strategic guidance and perspectives as we continue to launch RELYVRIO and ALBRIOZA and focus on bringing innovative treatments to the neurodegenerative disease community.”\n\n“Amylyx has the potential to change the treatment landscape for people living with ALS, and I am delighted to join the Board at this pivotal time,” said Ms. Firestone. “I look forward to coll...